This 78 week study is assessing the safety and efficacy of the medication Bapineuzumab in treating patients with mild to moderate Alzheimer’s disease.
Major Inclusion/Exclusion
- Ages 50- 89 yrs.
- MMSE 16-26 inclusive
- Auto-immune disease is excluded
- History of stroke is excluded